Dr. Gregory Bell was appointed Monitor by the FTC in several healthcare transactions to monitor Respondents’ compliance with post-merger divestiture obligations and other related requirements of the agreement. Dr. Bell and the CRA team complied with all monitor obligations, including conducting weekly and bi-weekly calls with the respective parties, and submitting a monthly report to the FTC on activities, issues, and opinions related to the divestiture obligations.
CRA's RADAR Insights: Evolution of manufacturer-set list prices and GKV rebates for orphan drugs - Part 2
RADAR contains all orphan drugs (ODs) that received European Medicines Agency (EMA) marketing authorisation between July 1, 2013, and September 30, 2024. For...